Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1986;34(3):285-91.

Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. II. Antiproliferative activity of cyclophosphamide and ifosfamide enantiomers

  • PMID: 3592932
Comparative Study

Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. II. Antiproliferative activity of cyclophosphamide and ifosfamide enantiomers

M Paprocka et al. Arch Immunol Ther Exp (Warsz). 1986.

Abstract

The present studies on antiproliferative activity of cyclophosphamide and ifosfamide /+/R and /-/S enantiomers followed the earlier described differences in their antitumour activity. P-388 leukemic cells in LCFU (Leukemic Colony Forming Units) assay and Lewis lung cells in experimental metastasis assay were used as models of tumour cells. Bone marrow stem cells were applied as models of normal proliferating cells in NCFU-(Normal Colony Forming Units) and RPNCFU (Rapidly Proliferating Normal Colony Forming Units) tests. In all four models /-/S enantiomers exerted higher antiproliferative effect, than their counterparts. Antiproliferative activity of /+/RS cyclophosphamide and ifosfamide appeared to be exactly intermediate between /+/R and /-/S forms. These data, precisely differentiating the effect of /+/R, /-/S and / +/- /RS forms, confirmed the earlier described, higher antitumour effect of /-/S enantiomers of cyclophosphamide and ifosfamide.

PubMed Disclaimer

Similar articles

Publication types

LinkOut - more resources